International Journal of Clinical Oncology

, Volume 16, Issue 2, pp 125–132

Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis

  • Terence C. Chua
  • Akshat Saxena
  • Francis Chu
  • S. Patrick Butler
  • Richard J. Quinn
  • Derek Glenn
  • David L. Morris
Original Article

DOI: 10.1007/s10147-010-0143-9

Cite this article as:
Chua, T.C., Saxena, A., Chu, F. et al. Int J Clin Oncol (2011) 16: 125. doi:10.1007/s10147-010-0143-9

Abstract

Background

Resection of hepatocellular carcinoma (HCC) is potentially curative; however, recurrence is common. To date, few or no effective adjuvant therapies have been adequately investigated. This study evaluates the efficacy of adjuvant iodine-131-lipiodol after hepatic resection through the experience of a single-center hepatobiliary service of managing this disease.

Patients and methods

All patients who underwent hepatic resection for HCC and received adjuvant iodine-131-lipiodol between January 1991 and August 2009 were selected for inclusion into the experimental group. A group composed of patients treated during the same time period without adjuvant iodine-131-lipiodol was identified through the unit’s HCC surgery database for comparison. The endpoints of this study were disease-free survival and overall survival.

Results

Forty-one patients who received adjuvant iodine-131-lipiodol after hepatic resection were compared with a matched group of 41 patients who underwent hepatic resection only. The median disease-free and overall survival were 24 versus 10 months (P = 0.032) and 104 versus 19 months (P = 0.001) in the experimental and control groups, respectively. Rates of intrahepatic-only recurrences (73 vs. 37%; P = 0.02) and surgical and nonsurgical treatments for recurrences (84 vs. 56%; P = 0.04) were higher in the experimental group compared to the control group.

Conclusion

The finding of this study corroborates the current evidence from randomized and nonrandomized trials that adjuvant iodine-131-lipiodol improves disease-free and overall survival in patients with HCC after hepatic resection. The lengthened disease-free survival after adjuvant iodine-131-lipiodol allows for further disease-modifying treatments to improve the overall survival.

Keywords

Hepatocellular carcinomaLiver resectionHepatectomyIodine-131Lipiodol

Copyright information

© Japan Society of Clinical Oncology 2010

Authors and Affiliations

  • Terence C. Chua
    • 1
  • Akshat Saxena
    • 1
  • Francis Chu
    • 1
  • S. Patrick Butler
    • 2
  • Richard J. Quinn
    • 2
  • Derek Glenn
    • 3
  • David L. Morris
    • 1
  1. 1.Hepatobiliary and Surgical Oncology Unit, Department of SurgerySt George Hospital, University of New South WalesSydneyAustralia
  2. 2.Department of Nuclear MedicineSt George Hospital, University of New South WalesSydneyAustralia
  3. 3.Department of RadiologySt George Hospital, University of New South WalesSydneyAustralia